Drug Profile


Alternative Names: BIIR 561 CL

Latest Information Update: 14 Jun 2001

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiepileptic drugs; Neuroprotectants; Oxadiazoles; Small molecules
  • Mechanism of Action AMPA receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Epilepsy; Neurological disorders

Most Recent Events

  • 14 Jun 2001 No-Development-Reported for Epilepsy in Germany (Unknown route)
  • 14 Jun 2001 No-Development-Reported for Neurological disorders in Germany (Unknown route)
  • 29 May 2000 BIIR 561 CL is now called irampanel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top